Importance of underlying mechanism and genotype on outcome of sepsis trials.
McIntyre
L
L
Walley
K R
KR
D020022:Genetic Predisposition to Disease / Q000235:genetics*; D005838:Genotype; D006801:Humans; D007074:Immunoglobulin G / Q000276:immunology / Q000627:therapeutic use*; D007143:Immunoglobulin Heavy Chains; D007142:Immunoglobulin gamma-Chains; D007249:Inflammation; D018124:Receptors, Tumor Necrosis Factor / Q000276:immunology / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use*; D012107:Research Design / Q000592:standards; D018805:Sepsis / Q000188:drug therapy* / Q000235:genetics* / Q000276:immunology / Q000401:mortality; D012772:Shock, Septic / Q000188:drug therapy* / Q000235:genetics* / Q000276:immunology / Q000401:mortality; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
D007074:Immunoglobulin G; D007143:Immunoglobulin Heavy Chains; D007142:Immunoglobulin gamma-Chains; D018124:Receptors, Tumor Necrosis Factor; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; C099374:Ro 45-2081